Chun-kang Chang-Chunkang

600 Yishan Road
Shanghai, 200233, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Clinical Characteristics and Prognosis Analysis of MDS-RS Patients with Wild-Type SF3B1

Clinical Characteristics and Prognosis Analysis of MDS-RS Patients with Wild-Type SF3B1

Journal: Zhongguo shi yan xue ye xue za zhi

Published: June 02, 2026

Targeting RBPMS selectively eliminates FOXO1-mediated stem cell signatures in mouse models of acute myeloid leukemia.

Targeting RBPMS selectively eliminates FOXO1-mediated stem cell signatures in mouse models of acute myeloid leukemia.

Journal: Science translational medicine

Published: May 06, 2026

Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome.

Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome.

Journal: Science translational medicine

Published: April 01, 2026

Molecular characterization and improved risk stratification of myelodysplastic syndromes with bone marrow fibrosis through integration of TP53 and MPL mutations.

Molecular characterization and improved risk stratification of myelodysplastic syndromes with bone marrow fibrosis through integration of TP53 and MPL mutations.

Journal: Discover oncology

Published: November 11, 2025

Deficiency of Setd2 in mesenchymal stem cells facilitates the progression of myelodysplastic syndrome to leukemia.

Deficiency of Setd2 in mesenchymal stem cells facilitates the progression of myelodysplastic syndrome to leukemia.

Journal: Molecular medicine (Cambridge, Mass.)

Published: July 16, 2025

A feasibility study of [18F] FDG PET/CT radiomics in predicting high-risk cytogenetic abnormalities in multiple myeloma.

A feasibility study of [18F] FDG PET/CT radiomics in predicting high-risk cytogenetic abnormalities in multiple myeloma.

Journal: EJNMMI research

Published: June 20, 2025

A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study.

A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study.

Journal: European journal of pharmacology

Published: April 03, 2025

Prognostic impact of somatic mutations and additional chromosomal abnormalities in patients with myelodysplastic syndromes and chromosome 20q deletion.

Prognostic impact of somatic mutations and additional chromosomal abnormalities in patients with myelodysplastic syndromes and chromosome 20q deletion.

Journal: Clinical and experimental medicine

Published: January 19, 2025

Validation and improvement of the molecular international prognostic scoring system in Chinese patients with myelodysplastic syndromes.

Validation and improvement of the molecular international prognostic scoring system in Chinese patients with myelodysplastic syndromes.

Journal: Annals of hematology

Published: October 07, 2024

Eltrombopag restores proliferative capacity and adipose-osteogenic balance of mesenchymal stromal cells in low-risk myelodysplastic syndromes.

Eltrombopag restores proliferative capacity and adipose-osteogenic balance of mesenchymal stromal cells in low-risk myelodysplastic syndromes.

Journal: European journal of pharmacology

Published: June 24, 2024

Chidamide Promotes Osteogenic Differentiation of Bone Marrow Mesenchymal Stromal Cells from Patients with Myelodysplastic Syndromes

Chidamide Promotes Osteogenic Differentiation of Bone Marrow Mesenchymal Stromal Cells from Patients with Myelodysplastic Syndromes

Journal: Zhongguo shi yan xue ye xue za zhi

Published: April 25, 2024

ROBO1 deficiency impairs HSPC homeostasis and erythropoiesis via CDC42 and predicts poor prognosis in MDS.

ROBO1 deficiency impairs HSPC homeostasis and erythropoiesis via CDC42 and predicts poor prognosis in MDS.

Journal: Science advances

Published: November 29, 2023

Showing 1-12 of 79

Last Updated: 09/26/2026